245 related articles for article (PubMed ID: 19875548)
1. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
Marchetti P; Lupi R; Del Guerra S; Bugliani M; D'Aleo V; Occhipinti M; Boggi U; Marselli L; Masini M
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S178-83. PubMed ID: 19875548
[No Abstract] [Full Text] [Related]
2. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment.
Marchetti P; Dotta F; Lauro D; Purrello F
Regul Pept; 2008 Feb; 146(1-3):4-11. PubMed ID: 17889380
[TBL] [Abstract][Full Text] [Related]
3. [The beta cell in diabetes].
Lenzen S
Dtsch Med Wochenschr; 2011 May; 136(21):1123-7. PubMed ID: 21590632
[No Abstract] [Full Text] [Related]
4. Pancreatic β cells: Gatekeepers of type 2 diabetes.
Park YJ; Woo M
J Cell Biol; 2019 Apr; 218(4):1094-1095. PubMed ID: 30696700
[TBL] [Abstract][Full Text] [Related]
5. [Pathogenic mechanism of type 2 diabetes mellitus from impaired glucose tolerance/borderline type and its reversibility].
Yoshimoto K; Ozawa S; Ishida H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():95-9. PubMed ID: 15779352
[No Abstract] [Full Text] [Related]
6. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
[TBL] [Abstract][Full Text] [Related]
7. The beta-cell in type 2 diabetes and in obesity.
Rutter GA; Parton LE
Front Horm Res; 2008; 36():118-134. PubMed ID: 18230899
[TBL] [Abstract][Full Text] [Related]
8. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
Reaven GM
Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
[No Abstract] [Full Text] [Related]
9. Defining and characterizing the progression of type 2 diabetes.
Fonseca VA
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S151-6. PubMed ID: 19875543
[No Abstract] [Full Text] [Related]
10. Impaired beta cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects.
Walker M; Mari A; Jayapaul MK; Bennett SM; Ferrannini E
Diabetologia; 2005 Dec; 48(12):2470-6. PubMed ID: 16261308
[TBL] [Abstract][Full Text] [Related]
11. Role of High-Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control.
Manandhar B; Cochran BJ; Rye KA
J Am Heart Assoc; 2020 Jan; 9(1):e013531. PubMed ID: 31888429
[No Abstract] [Full Text] [Related]
12. Insulin response in relation to insulin sensitivity: an appropriate beta-cell response in black South African women: response to Goedecke et al.
Joffe BI; Distiller LA
Diabetes Care; 2009 Oct; 32(10):e123; author reply e124. PubMed ID: 19793997
[No Abstract] [Full Text] [Related]
13. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset.
Ferrannini E; Mari A; Nofrate V; Sosenko JM; Skyler JS;
Diabetes; 2010 Mar; 59(3):679-85. PubMed ID: 20028949
[TBL] [Abstract][Full Text] [Related]
14. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
15. A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment.
Podell BK; Ackart DF; Richardson MA; DiLisio JE; Pulford B; Basaraba RJ
Dis Model Mech; 2017 Feb; 10(2):151-162. PubMed ID: 28093504
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat.
Cummings BP; Digitale EK; Stanhope KL; Graham JL; Baskin DG; Reed BJ; Sweet IR; Griffen SC; Havel PJ
Am J Physiol Regul Integr Comp Physiol; 2008 Dec; 295(6):R1782-93. PubMed ID: 18832086
[TBL] [Abstract][Full Text] [Related]
17. Type II diabetes mellitus.
Edelman SV
Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
[TBL] [Abstract][Full Text] [Related]
18. Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better".
Kaneto H; Matsuoka TA; Kimura T; Obata A; Shimoda M; Kamei S; Mune T; Kaku K
J Diabetes; 2016 Mar; 8(2):183-9. PubMed ID: 26223490
[TBL] [Abstract][Full Text] [Related]
19. THE PHYSIOLOGY BEHIND DIABETES MELLITUS IN PATIENTS WITH PHEOCHROMOCYTOMA: A REVIEW OF THE LITERATURE.
Mesmar B; Poola-Kella S; Malek R
Endocr Pract; 2017 Aug; 23(8):999-1005. PubMed ID: 28613940
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes mellitus: a disease of the governance of the glucose-insulin system: an experimental metabolic control analysis study.
Trombetta M; Boselli L; Cretti A; Calì A; Vettore M; Caruso B; Dorizzi R; Avogaro A; Muggeo M; Bonora E; Bonadonna RC
Nutr Metab Cardiovasc Dis; 2013 Jan; 23(1):23-30. PubMed ID: 21937205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
